This clinical trial was performed at the Institute of Neurological Sciences, Southern General, Greater Glasgow, Scotland. The patient is an elderly Scotsman who was given very low doses of stem cells, and according to his doctors he is doing well. This is the first of twelve patients who will take part in the trial, which will all be men over 60 years of age who have improved very little or not at all. This study, called Pilot Investigation of Stem Cells in Stroke (PISCES), is the first of its kind in the world. Patients will be monitored over the course of two years to determine the effects of using stem cell treatment.
This first phase of the trial is meant to determine the safety of ReN001 on patients who have become disabled due to ischemic stroke, which accounts for about 75% of all strokes. It will also be testing whether implanting stem cells can treat damaged areas of the brain, helping to improve patients quality of life for patients who have had an ischaemic stroke.
Stroke is the main cause of disability in industrialized countries and the third cause of death. In the US 795,000 have a stroke each year, and the vast majority of people who get a stroke are aged over 65 years.
Professor Muir, who headed the research team, said that. "We hope that in future it will lead on to larger studies to determine the effects of stem cells on the disabilities that result from stroke."
By Russ Allen
Source: The Stroke Association